The Signatera test is a type of "liquid biopsy" — a blood test that looks for tiny fragments of tumor DNA circulating in the bloodstream. It's designed to detect whether cancer cells are still present or returning after treatment, even before they'd show up on a scan.
It works by analyzing the genetic profile of a person's Show Full Answer
The Signatera test is a type of "liquid biopsy" — a blood test that looks for tiny fragments of tumor DNA circulating in the bloodstream. It's designed to detect whether cancer cells are still present or returning after treatment, even before they'd show up on a scan.
It works by analyzing the genetic profile of a person's specific tumor, then checking the blood for matching DNA fragments. This makes it a personalized test, tailored to each individual's cancer. For lung cancer specifically, liquid biopsies like Signatera can be useful for:
- Detecting residual cancer cells after treatment
- Monitoring for recurrence over time
- Helping guide decisions about further treatment
It's worth noting that while this technology is promising and growing in use, it may not be available or recommended in every situation. It's always best to ask an oncologist whether this test makes sense given a specific treatment history and current monitoring plan.
A MyLungCancerTeam member shared a similar experience of getting blood tests at a three-year checkup and receiving an all-clear result — showing how blood-based monitoring can be a reassuring part of post-treatment care.
August 4
Join
Your Privacy Choices
